tiprankstipranks
Immunocore Holdings Plc (IMCR)
NASDAQ:IMCR
US Market
IMCR
Immunocore Holdings
RESEARCH TOOLSreports
Want to see IMCR full AI Analyst Report?

Immunocore Holdings (IMCR) Stock Forecast & Price Target

252 Followers
See the Price Targets and Ratings of:

IMCR Analyst Ratings

Moderate Buy
9Ratings
Moderate Buy
6 Buy
3 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Immunocore
Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IMCR Stock 12 Month Forecast

Average Price Target

$62.67
▲(99.26% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Immunocore Holdings in the last 3 months. The average price target is $62.67 with a high forecast of $100.00 and a low forecast of $33.00. The average price target represents a 99.26% change from the last price of $31.45.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"$27","64":"$64","101":"$101","45.5":"$45.5","82.5":"$82.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$62.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,45.5,64,82.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.31,35.67076923076923,41.03153846153846,46.392307692307696,51.75307692307692,57.113846153846154,62.47461538461539,67.83538461538461,73.19615384615385,78.55692307692307,83.9176923076923,89.27846153846154,94.63923076923078,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.31,32.798974358974355,35.287948717948716,37.776923076923076,40.265897435897436,42.7548717948718,45.24384615384616,47.73282051282051,50.22179487179487,52.71076923076923,55.19974358974359,57.68871794871795,60.17769230769231,{"y":62.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.31,30.516923076923074,30.723846153846154,30.93076923076923,31.13769230769231,31.344615384615384,31.55153846153846,31.75846153846154,31.965384615384615,32.17230769230769,32.379230769230766,32.58615384615385,32.793076923076924,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.93,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.09,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.59,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.04,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.67,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$100.00Average Price Target$62.67Lowest Price Target$33.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on IMCR
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$90→$100
Buy
217.97%
Upside
Reiterated
04/23/26
H.C. Wainwright Remains a Buy on Immunocore Holdings (IMCR)
Oppenheimer Analyst forecast on IMCR
Jeff Jones
Oppenheimer
Oppenheimer
$86
Buy
173.45%
Upside
Reiterated
04/20/26
Analysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Tonix Pharma (TNXP)
Mizuho Securities Analyst forecast on IMCR
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$38
Hold
20.83%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Immunocore Holdings (NASDAQ: IMCR)
Wells Fargo Analyst forecast on IMCR
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$60
Buy
90.78%
Upside
Reiterated
04/14/26
Analysts Are Bullish on Top Healthcare Stocks: Takeda Pharmaceutical Co (TKPHF), Immunocore Holdings (IMCR)
Needham Analyst forecast on IMCR
Gil Blum
Needham
Needham
$75
Buy
138.47%
Upside
Reiterated
04/14/26
Immunocore (IMCR): Clinical Momentum, Credible Management, and Industry Visibility Support Buy Rating
Jefferies Analyst forecast on IMCR
Faisal Khurshid
Jefferies
Jefferies
$33
Hold
4.93%
Upside
Downgraded
03/15/26
Immunocore downgraded to Hold from Buy at JefferiesImmunocore downgraded to Hold from Buy at Jefferies
Morgan Stanley Analyst forecast on IMCR
Sean Laaman
Morgan Stanley
Morgan Stanley
$40
Hold
27.19%
Upside
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (NASDAQ: IMCR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Schrodinger (NASDAQ: SDGR)
Goldman Sachs Analyst forecast on IMCR
Rajan Sharma
Goldman Sachs
Goldman Sachs
$74→$72
Buy
128.93%
Upside
Reiterated
02/26/26
TD Cowen Analyst forecast on IMCR
Tyler Van Buren
TD Cowen
TD Cowen
$60
Buy
90.78%
Upside
Reiterated
02/25/26
Immunocore: Sustained Kimmtrak Momentum and Pipeline Catalysts Support Buy Rating
UBS Analyst forecast on IMCR
Michael Yee
UBS
UBS
$55
Buy
74.88%
Upside
Initiated
01/06/26
Immunocore upgraded to Buy from Sell at UBSImmunocore upgraded to Buy from Sell at UBS
Guggenheim Analyst forecast on IMCR
Paul Jeng
Guggenheim
Guggenheim
―
Hold
―
Initiated
09/17/25
Immunocore assumed with a Neutral at GuggenheimImmunocore assumed with a Neutral at Guggenheim
Leerink Partners Analyst forecast on IMCR
Jonathan Chang
Leerink Partners
Leerink Partners
$67→$60
Buy
90.78%
Upside
Reiterated
08/11/25
Leerink Partners Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)
Barclays Analyst forecast on IMCR
Peter Lawson
Barclays
Barclays
$52
Buy
65.34%
Upside
Reiterated
08/08/25
Barclays Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)
Deutsche Bank Analyst forecast on IMCR
James Shin
Deutsche Bank
Deutsche Bank
$65
Buy
106.68%
Upside
Initiated
05/27/25
Immunocore Holdings (IMCR) Receives a New Rating from Deutsche Bank
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on IMCR
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$90→$100
Buy
217.97%
Upside
Reiterated
04/23/26
H.C. Wainwright Remains a Buy on Immunocore Holdings (IMCR)
Oppenheimer Analyst forecast on IMCR
Jeff Jones
Oppenheimer
Oppenheimer
$86
Buy
173.45%
Upside
Reiterated
04/20/26
Analysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Tonix Pharma (TNXP)
Mizuho Securities Analyst forecast on IMCR
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$38
Hold
20.83%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Immunocore Holdings (NASDAQ: IMCR)
Wells Fargo Analyst forecast on IMCR
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$60
Buy
90.78%
Upside
Reiterated
04/14/26
Analysts Are Bullish on Top Healthcare Stocks: Takeda Pharmaceutical Co (TKPHF), Immunocore Holdings (IMCR)
Needham Analyst forecast on IMCR
Gil Blum
Needham
Needham
$75
Buy
138.47%
Upside
Reiterated
04/14/26
Immunocore (IMCR): Clinical Momentum, Credible Management, and Industry Visibility Support Buy Rating
Jefferies Analyst forecast on IMCR
Faisal Khurshid
Jefferies
Jefferies
$33
Hold
4.93%
Upside
Downgraded
03/15/26
Immunocore downgraded to Hold from Buy at JefferiesImmunocore downgraded to Hold from Buy at Jefferies
Morgan Stanley Analyst forecast on IMCR
Sean Laaman
Morgan Stanley
Morgan Stanley
$40
Hold
27.19%
Upside
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (NASDAQ: IMCR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Schrodinger (NASDAQ: SDGR)
Goldman Sachs Analyst forecast on IMCR
Rajan Sharma
Goldman Sachs
Goldman Sachs
$74→$72
Buy
128.93%
Upside
Reiterated
02/26/26
TD Cowen Analyst forecast on IMCR
Tyler Van Buren
TD Cowen
TD Cowen
$60
Buy
90.78%
Upside
Reiterated
02/25/26
Immunocore: Sustained Kimmtrak Momentum and Pipeline Catalysts Support Buy Rating
UBS Analyst forecast on IMCR
Michael Yee
UBS
UBS
$55
Buy
74.88%
Upside
Initiated
01/06/26
Immunocore upgraded to Buy from Sell at UBSImmunocore upgraded to Buy from Sell at UBS
Guggenheim Analyst forecast on IMCR
Paul Jeng
Guggenheim
Guggenheim
―
Hold
―
Initiated
09/17/25
Immunocore assumed with a Neutral at GuggenheimImmunocore assumed with a Neutral at Guggenheim
Leerink Partners Analyst forecast on IMCR
Jonathan Chang
Leerink Partners
Leerink Partners
$67→$60
Buy
90.78%
Upside
Reiterated
08/11/25
Leerink Partners Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)
Barclays Analyst forecast on IMCR
Peter Lawson
Barclays
Barclays
$52
Buy
65.34%
Upside
Reiterated
08/08/25
Barclays Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)
Deutsche Bank Analyst forecast on IMCR
James Shin
Deutsche Bank
Deutsche Bank
$65
Buy
106.68%
Upside
Initiated
05/27/25
Immunocore Holdings (IMCR) Receives a New Rating from Deutsche Bank
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunocore Holdings

3 Months
xxx
Success Rate
6/15 ratings generated profit
40%
Average Return
-5.75%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -5.75% per trade.
1 Year
Peter LawsonBarclays
Success Rate
6/18 ratings generated profit
33%
Average Return
-10.87%
Copying Peter Lawson's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -10.87% per trade.
2 Years
xxx
Success Rate
2/18 ratings generated profit
11%
Average Return
-18.93%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 11.11% of your transactions generating a profit, with an average return of -18.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMCR Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
11
11
10
10
14
Buy
0
0
0
0
0
Hold
2
3
5
6
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
14
15
16
20
In the current month, IMCR has received 14 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. IMCR average Analyst price target in the past 3 months is 62.67.
Each month's total comprises the sum of three months' worth of ratings.

IMCR Financial Forecast

IMCR Earnings Forecast

Next quarter’s earnings estimate for IMCR is -$0.27 with a range of -$0.42 to -$0.10. The previous quarter’s EPS was $0.00. IMCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.
Next quarter’s earnings estimate for IMCR is -$0.27 with a range of -$0.42 to -$0.10. The previous quarter’s EPS was $0.00. IMCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.

IMCR Sales Forecast

Next quarter’s sales forecast for IMCR is $107.08M with a range of $99.25M to $112.30M. The previous quarter’s sales results were $103.05M. IMCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.
Next quarter’s sales forecast for IMCR is $107.08M with a range of $99.25M to $112.30M. The previous quarter’s sales results were $103.05M. IMCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.

IMCR Stock Forecast FAQ

What is IMCR’s average 12-month price target, according to analysts?
Based on analyst ratings, Immunocore Holdings Plc’s 12-month average price target is 62.67.
    What is IMCR’s upside potential, based on the analysts’ average price target?
    Immunocore Holdings Plc has 99.26% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IMCR a Buy, Sell or Hold?
          Immunocore Holdings Plc has a consensus rating of Moderate Buy which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Immunocore Holdings Plc’s price target?
            The average price target for Immunocore Holdings Plc is 62.67. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $100.00 ,the lowest forecast is $33.00. The average price target represents 99.26% Increase from the current price of $31.45.
              What do analysts say about Immunocore Holdings Plc?
              Immunocore Holdings Plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of IMCR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.